Product/Composition:- | Dolutegravir + Abacavir + Lamivudine |
---|---|
Strength:- | 50 mg / 600 mg / 300 mg |
Form:- | Tablet |
Reference Brands:- | Triumeq(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Dolutegravir + Abacavir + Lamivudine, sold as Triumeq, is a once-daily HIV-1 treatment combining three antiretrovirals in one pill. It offers strong viral suppression, is FDA and EMA approved, and is recommended for patients who are HLA-B*5701 negative.
Dolutegravir + Abacavir + Lamivudine is a fixed-dose combination antiretroviral medication used for the treatment of HIV-1 infection. Marketed under the brand name Triumeq, this once-daily oral tablet combines Dolutegravir (an integrase inhibitor), Abacavir, and Lamivudine (both NRTIs) to block HIV replication and reduce viral load. Approved by the US FDA and EMA, it is recommended for adults and adolescents who are HLA-B*5701 negative, with no resistance to any of the components. Triumeq simplifies HIV treatment by combining three powerful agents in one pill, offering high efficacy, strong viral suppression, and improved adherence for long-term HIV management.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications